MCF7/LetR-1 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
MCF7/LetR-3 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (4)
- Inventor Info
Info
| Catalogue Number | 152549 |
| Antigen/Gene or Protein Targets | Letrozole resistant |
| Parental Line | MCF7 |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast Cancer |
| Relevance | The MCF7/LetR-3 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI letrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment. |
| Production Details | Letrozole-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10−7 M testosterone. A culture of MCF-7 cells were treated with 10−6 M letrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with letrozole. After ~2–3 months, the isolated colonies gave rise to letrozole-resistant cell lines, which could be grown in letrozole-containing medium with a weekly split ratio of ~1:25. The MCF-7 cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Breast cancer cell line resistant to the aromatase inhibitor letrozole. Estrogen receptor positive. |
| Recommended Growing Conditions | Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 1 uM letrozole. |
| Notes |
Human breast cancer cell line derived from MCF-7 cells Other related cell lines: - LetR-1, LetR-2 and LetR-4 resistant to the non-steroidal AI letrozole - ExeR-1, ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI exemestane - AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole Passage 436 (AL3136, AL3137) |
| Cellosaurus ID | CVCL_5A19 |
MCF7/LetR-2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
MCF7/LetR-4 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
References: 4 entries
Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Europe PMC ID: 25667100
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Europe PMC ID: 25625755
Add a reference
References: 4 entries
Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Add a reference
